Compare Essex Property Trust, Inc. (ESS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Essex Property Trust, Inc. trades at $269.13 (market cap $17.26B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: Essex Property Trust, Inc. is far larger — about 153.8× Inovio Pharmaceuticals Inc's market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| ESS | INO | |
|---|---|---|
Market Cap | $17.26B | $112.19M |
Volume | 454,464 | 3,201,278 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $2.65 |
52-Week Low | $239.61 | $0.66 |
Typical Hold Time | 111 Days | 43 Days |
Enterprise Value | $23.86B | $83.51M |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $268.05, down 1.63% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with Q3 2026 results pending. Revenue reached $1.89B in 2025, with a net income margin of 21.48%, while valuation ratios like a P/E of 41.83 suggest a premium. Recent news highlights strong Q2 2026 results, raised guidance, and a declared dividend of $2.59 per share.
The outlook is cautiously optimistic, supported by operational strength and resolved litigation, but high valuation and earnings volatility pose risks. Analyst consensus is a Buy with a $303.41 price target, indicating potential upside, though investors should monitor debt levels and consistent earnings delivery against expectations.
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
